Month: April 2021


Tak lands at Candel, with plans to speed up development of immunotherapy’s play late-stage assets

Who are Candel Therapeutics?

Oncolytic virus company Candel has bolstered its executive team with a quartet of industry veterans headlined by new CEO Paul Peter Tak, a biotech entrepreneur and GSK veteran who plans to raise venture money to accelerate development of the company’s late-stage pipeline while adding discovery programs.

Boston-based Candel Therapeutics, formerly known as Advantagene Inc., is developing two different oncolytic virus platforms with the most advanced program in Phase III testing to treat prostate cancer.

But with the majority of the company’s more than 20 years of existence spent subsisting on federal funding, one of Tak’s primary focuses will be to accelerate the pace of development.

“There are not many biotech companies out there almost in stealth mode that are in Phase III, pre-IPO in cancer immunotherapy,” Tak told BioCentury. “I thought this is where I can have an impact with my background in academia, pharma and biotech, to help build this business ready for the next stage.”

Who is Paul Peter-Tak?

Tak was most recently president and CEO of Kintai Therapeutics and a venture partner at Flagship Pioneering. Before that he was SVP and chief immunology officer at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).

Over the past two-plus months he’s added three other executives to the team. John Canepa was named Candel’s CFO. He was most recently CFO at degenerative disease company Frequency Therapeutics Inc. (NASDAQ:FREQ), which last year raised $88.6 million in an IPO.

Also joining Candel is CBO Nathan Caffo and Chief Regulatory Officer Susan Stewart. Caffo was previously CBO at immuno-oncology company ALX Oncology Holdings Inc. (NASDAQ:ALXO),while Stewart, who serves as an independent consultant, is also chief regulatory officer at Kaleido Biosciences Inc. (NASDAQ:KLDO). Candel’s prior CEO, founder Estuardo Aguilar-Cordova, has become CSO, while Laura Aguilar remains CMO.

As Tak continues to expand Candel’s management team, he plans to begin fund-raising to add fresh capital to the company. Candel was founded in 1999 but didn’t raise its first institutional financing round until 2016, with subsequent series B and C rounds last year that bring total venture capital raised to $67.6 million.

Tak said that as the company has been efficient with its captial there’s still plenty of cash to execute on existing programs, but he aims to accelerate the development of the pipeline while adding new discovery programs.

Aglatimagne Besadenovec

Candel’s lead program is aglatimagene besadenovec (CAN-2409), a replication-deficient oncolytic adenovirus that delivers the HSV thymidine kinase gene to cancer cells. Patients are then dosed with valacyclovir, which the locally expressed thymidine kinase enzyme converts into a toxic metabolite, killing the tumor cells and creating a pro-inflammatory microenvironment that leads to increased T cell infiltration.

Aglatimagene is in a Phase III trial for intermediate or high-risk prostate cancer patients and a Phase II trial for prostate cancer patients on active surveillance. The same program is being tested in three other indications:

  • a Phase III trial starting next year in first-line glioblastoma multiforme (GBM)
  • Phase II studies in pancreatic cancer and non-small cell lung cancer (NSCLC).

Candel’s second platform is a novel HSV vector. The lead program there is CAN-3110, a replication-competent HSV oncolytic virus that can selfamplify and is in Phase I testing to treat recurrent glioblastoma.

Tak said data from the Phase III prostate cancer trial is expected in 2023, while next year Candel expects Phase II data from the active surveillance prostate cancer trial and the NSCLC trial; and Phase I data for aglatimagene plus Opdivo nivolumab in newly diagnosed GBM and for CAN-3110 in recurrent glioblastoma.

Tak said he’s also starting a discovery program of novel HSV oncolytic viruses that can modulate the tumor microenvironment. Other companies such as PsiOxus Therapeutics Ltd., Replimune Group Inc. (NASDAQ:REPL) and Transgene S.A. (Euronext:TNG) have “armed” oncolytic virus platforms that carry transgenes that express molecules that can modulate the tumor locally.

GSK-Backed Sitryx Launches With Six Immunometabolism Eggs In Its Basket

GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. CEO Neil Weir outlines Sitryx’s raison d’etre.

Who created Sitryx?

Chemical assets from GlaxoSmithKline PLC and target biology insights from high-profile academic founders form the basis for new company Sitryx, which has been launched with $30m in series A funding. Focused on developing disease-modifying treatments for autoimmune/inflammatory conditions and cancer, it is working on six early-stage projects to target immunometabolic pathways with small-molecule candidates. The company sprang out of the Immunology Network set up at GSK by Paul Peter Tak, who last month left the company after seven years and who is a co-founder of Sitryx.

“We have set ourselves up to be leaders in the field of immunometabolism,” explained CEO Neil Weir, who joined the company as its first employee in April 2018. He was previously SVP Discovery at UCB Pharma. The company’s assets include the tangible assets from GSK and “biological insights into pathways and as yet unpublished data from the founders’ labs around the connectivity of targets to human disease,” Weir told Scrip. “We’ve not encamped in one specific area; our targets cover a broad range of metabolic pathways through the insights that have come from our founders in glycolysis, the TCA [tricarboxylic acid] cycle and in pathways that feed into the TCA cycle.”

Sitryx has six academic founders from the world of immunology and metabolism:

Houman Ashrafian – Partner at SV Health Investors and Visiting Professor and Head of Experimental Therapeutics at University of Oxford

Luke O’Neill – Professor of Biochemistry, School of Biochemistry and Immunology at Trinity College Dublin

Jonathan Powell – Professor of Oncology and Associate Director, Institute for Cancer Immunotherapy, Johns Hopkins University

Jeff Rathmell – Professor of Cancer Biology and Director, Vanderbilt Center for Immunobiology

Michael Rosenblum – Assistant Professor, UCSF School of Medicine

Paul Peter Tak – formerly Chief Immunology Officer and SVP at GlaxoSmithKline, and Professor of Medicine at Amsterdam University Medical Centre

What is immunometabolism?

Tak explained to Scrip that it had been Luke O’Neill through his work with GSK’s Immunology Network who had helped identify immunometabolism as “potentially the next big thing in immunology.” Unlike previous work targeting metabolic pathways to starve tumor cells, “this is a fundamentally different approach where you actually target metabolic pathways to interfere with the immune system and thereby target the tumor cell,” Tak said, noting that such an approach is also relevant to diseases of auto-immunity.

While the fundamentals of metabolism are a fairly well understood already, attempting to drug metabolic pathways to change the behaviour of immune cells is still an emerging field, explained Weir. “And from what we can see and with the way we’re pursuing our targets, we’re not seeing other competitors.” With the breadth of experience of the founders and knowledge around different targets, Sitryx “doesn’t have all our eggs in one basket,” added the CEO: “There’s a breadth of portfolio here, it’s not just a single project. And it covers both innate and adaptive immune responses.”

The Future of Immuno-Oncology

The company is still at an early stage, and does not expect to begin identifying candidates to take into the clinic until late 2019, with first in human trials not expected before 2020.

To date, immuno-oncology has focused in large part on stimulating cell surface receptors using antibody treatments, but Sitryx is looking to develop small molecule oral and topical therapies that influence processes inside the cells. There may be potential to develop such treatments to be complementary to other therapies, but the company’s starting point is to view its candidates as standalone therapies, Weir said.

The programs are split between autoimmune/inflammatory and oncology conditions but “we will follow where the biology takes us, having set out on a path which starts off with a hypothesis as to where it’s pertinent,” the CEO noted, adding that the approach could also be applied to fibrosis.

Sitryx will have its own labs in Oxford Science Park but it will also work with founders, placing post-docs in their labs, as well as working with CROs. And GSK will support the company, for example helping it to understand and apply PROTACS (proteolysis targeting chimera) technology.

The series A round was co-led by SV Health Investors and Sofinnova Partners, with GSK and Longwood Fund also investing. GSK has no special rights on candidates emerging from Sitryx’s pipeline.

View Article:

Going with Your Gut Instinct

I’ve been interested in this field since before the term “microbiome” was coined. In the 1990s, I conducted research at Leiden University Medical Center on the role of microorganisms in the pathogenesis of rheumatoid arthritis (RA). We were the first to take biopsies from the target tissues of inflamed joints of patients with RA and other forms of inflammatory joint disease, and analyze them using 16s PCR. We detected microbial DNA in different forms of arthritis and predicted that it would be derived from the gut.


An exodus of pharma R&D leaders to small biotechs and start-ups over the last year reflects a new phase in the ecosystem’s churn of talent. But it’s not all loss for the pharmas. The transition is expected to help them access innovation by improving the quality and number of in-licensing opportunities.

This year, 25 senior leaders in R&D from 17 different pharma companies have departed to take CEO or other senior management positions at smaller biotechs. Eighteen of those execs joined companies that were founded or raised a series A round in the last three years.

Pharma leaders who are making the leap told BioCentury the hands-on access to research was a key part of the decision.

Read the full article and find out more about the changes to leadership in top research and development teams by clicking on the link below.

BioCentury Innovations

“Our philosophy is to be very open with the external world in terms of target identification and target validation. We compete in terms of molecules.”

While academic partnerships have become par for the course in pharma, GSK is going a step beyond the standard model of external alliances by bringing professors in-house with virtually unrestricted access to its activities. The initiative is the latest example of pharmas lowering their guard in order to both access cutting-edge science and foster the ecosystem’s future innovators.

Immunology Network working alongside GSK

It’s a necessary but worthwhile price to pay, according to Paul-Peter Tak, who created the program, dubbed Immunology Network, in 2015. Tak is Chief Immunology Officer and SVP of the R&D Pipeline at GlaxoSmithKline plc.

“Our philosophy is to be very open with the external world in terms of target identification and target validation. We compete in terms of molecules,” Tak told BioCentury.

The core of the Immunology Network involves providing academic researchers with three-year sabbaticals inside GSK’s R&D hub in Stevenage, where they are given a lab, personnel and access to the pharma’s technology, compound libraries and internal meetings and data.

Tak noted the program is “not transforming them into GSK employees. They continue to be employees of the university, and we reimburse the university.” Moreover, the researchers can take their discoveries with them when they leave.

“If they discover something within our facilities that’s completely based on their own research, then they actually own the IP. I think no other company has done it in this way,” said Tak.

Louise Modis, the Immunology Network’s scientific director, told BioCentury that the program’s IP terms boil down to the principle that “they own the biology IP that they bring and that they do, and GSK protects molecules that are going into the clinic.”

Thus far, the program has brought in seven investigators, expanded the indications of two internal programs, and founded an undisclosed newco in a white space area, which GSK is funding as a minority investor and has the option to buy.

Luke O’Neill, a program participant and a professor of inflammation research at Trinity College Dublin, gives GSK credit for creating something “brand new,” and based on the program’s success so far, thinks other companies should follow suit. “GSK was taking a risk, because nobody had done this before.”

Transplant Model

Tak joined GSK in 2011, and is one of the two primary leaders reporting to outgoing CSO and President of R&D Patrick Vallance, who on Jan. 1 will hand the reins over to Hal Barron, currently president of R&D at longevity company Calico LLC.

Vallance is leaving the pharma at the end of March to become the U.K. government’s chief science adviser and head of the government’s Office for Science. The Immunology Network program will continue under GSK’s new leadership.

Having spent the bulk of his career as an academic researcher and physician, Tak created the Immunology Network to fill what he believed was a crucial gap in the pharma’s extensive roster of external partnerships (see “Out of the Dark”).

“There was one piece missing. That piece was actually bringing in senior academics into GSK,” said Tak, who remains affiliated with University of Amsterdam, Ghent University and University of Cambridge. “We do this of course all the time to make them GSK employees. But here we did it differently, where they continue to do their academic research in a much more ‘bluesky thinking’ way.”

John Hamilton, a professor of medicine at University of Melbourne and the first investigator recruited into program, told BioCentury the program creates a microcosm inside the company that allows for unprescribed discoveries. “There’s no pressure for people to come up with targets, because that’s not how it really should work in academia. Some of the best results will probably come out of left field.”

GSK has toyed with various structures for partnering with academia, such as its Discovery Partnerships with Academia (DPAc) program, and for incubating innovation from GSK scientists within in its Discovery Performance Units (DPUs).

Tak noted that unlike the DPAc program, which is “focused on very specific projects that could lead to a medicine,” the Immunology Network is geared to capitalize on emerging areas that are further from the clinic. They can also fall outside the purview of the DPUs.

“When you talk about business development opportunities in fields that do not fit in the DPU’s territory, then people are not interested, because they need to be focused,” he said. “These very new opportunities are very high-risk, because there’s less data. So I think the Immunology Network can complement that model with the creation of new companies.”

While Tak’s background as a rheumatologist played a role in the program’s immunological focus, he said the field’s recent successes, and relevance to a broad range of therapeutic areas such as autoimmunity, cancer and neuroinflammation, made it “a very good starting point to work in a new model.”

Follow the link below to read the full article outlining the strategy for BioCentury Innovations.

Targeting Immuno-Inflammation: Where Industry and Academia Interface

Although inflammation is a necessary biological process in response to injury and disease, at abnormal levels it is also responsible for a significant annual health burden. Immune-mediated inflammatory disease is present at a prevalence of about 7% in the Western world and with an ever aging population this is set to rise. While treatments for some of the more common inflammatory disorders such as rheumatoid arthritis (RA) do exist, there is still a large unmet patient need as many sufferers do not achieve remission of symptoms even when using currently available therapies. Immuno-inflammation is one of GlaxoSmithKline (GSK)’s key therapeutic areas of interest. Helen Albert speaks to Paul-Peter Tak, Senior Vice President and Chief Immunology Officer at GSK, about his career and the work he is doing at GSK to encourage scientific innovation and target unhealthy inflammation in all its forms.

Paul-Peter Tak began his career in academia with a PhD in Immunology at the University of Leiden in the
Netherlands. He moved to the Academic Medical Center (AMC) of the University of Amsterdam in 1999, where he became Professor of Medicine. During that time, he worked very closely with the biotech and pharmaceutical industry as a consultant and started several companies including a biotech company developing a gene therapy for RA called Arthrogen. In 2011, he joined GSK as Senior Vice President and Global Head of Research and Development (R&D) in Immuno-inflammation, while still maintaining research links with the AMC.

In Jan 2016, he started as Senior Vice President for a group of therapy areas covering immuno-inflammation, oncology, dermatology and infectious diseases. He also currently leads the Development Steering Team which oversees late-stage development in R&D at GSK.

What made you decide to move from academia to industry and how have you found the transition?

I’m a physician, a physician scientist, and I studied medicine to influence the life of patients in a positive
way. I’ve always focused on three things in academia trying to be a really good physician for my patients and to listen to them and give them the best treatments of the day, that’s one. Second, to start to discover and develop new medicines for the future, and the third is of course about training and education of physicians who became medical specialists. I was the head of department in Amsterdam for 12 years, but I thought perhaps I could have a bigger impact on patients’ lives if I joined a company like GSK. If you develop medicines here that really make a difference, you have the potential to touch the lives of millions of patients. I decided that with the resources, the technology, the high level of the science
and the academic collaborations that GSK has that I could make a big difference here. So that was the reason that I joined. Of course it was a big step, because I was in a very senior role, also in an international organisation, and I didn’t really know what I was signing up for. I had worked very closely with industry, but I’d never been an employee of industry. But I think from the day that I joined I really enjoyed it, it was like stepping into a warm bath in many ways. What I really liked was the rigour of
the science here, the very high quality, the collaborative atmosphere and that people have a common goal to discover and develop medicines for patients who need them. At the same time, I have continued to be very strongly linked to the academic world, so I guess I have had the best of both worlds.

What is the GSK immunology network?

We have a lot of collaborations with universities and academic institutions and also with biotech and other pharmaceutical companies. I think we have more than 500 research partnerships, some of them are very strong. The Immunology Network, as I’ve called it, is I think, a very innovative model of working with academia and has different components. The first pillar of the network is the External Immunology Board; we work with absolutely top immunologists from around the world who all have a slightly different profile. For example, some people are focused on neuroimmunology, others on immunometabolics and so on. Then the second pillar is the immunology catalyst and this is for senior academics who want to come into GSK for an extended sabbatical. If selected, they can come and work in our facilities in Stevenage in the UK, which is one of the two major Research and Development hubs in the world for
GSK, where we give them support in terms of postdocs, personnel and the lab, but they continue to do their own independent research. They have a badge to get into our facilities, but they are not GSK employees. They continue to be employees from their university and we reimburse the university so they keep their academic independence, which is deliberately the model.

The third component is the Immunology Innovations Fund that I started. If there is a great idea in the
Immunology Catalyst, which does not fit into one of the current funding schemes, then I can use money from the Immunology Innovation Fund to bring it to the next inflection point and then we may decide to start a biotech company around it if the academics are interested, and then they would become the founders, or we might internalise it and it could become a GSK program. The 4th and last pillar is the organization of the Immunology Network Summit Meetings where the external immunology board members come together with the immunology catalyst members and the immunologists in GSK. They
are a bit like Keystone meetings, the level is similar, and it creates something completely new I think. So in part it is about internalising the external world and bringing in the independent academic voice into GSK.

What do you think are the hot topics in inflammation research right now?

Well there is a lot going on in inflammation. We call it immuno-inflammation, because it’s quite difficult to distinguish between the immunology and inflammation, as it’s so strongly linked. It is a very important field in terms of the prevalence of disease. Immunoinflammatory disorders are common and there is still a
very big unmet need. There are many conditions where we don’t have any treatments. For some of the conditions where we do have quite a lot of treatments, like RA, there is still a very big unmet need, because at least 50% of the patients do not achieve remission and that is the
goal of treatment. In the last 5 or 6 years, immunoinflammation at GSK has been quite successful. We’ve
built a very strong and holistic portfolio. I will give you a few examples, as these are what we believe are hot topics.

One example is the world of epigenetics, where of course we enter a completely new field where you ask the question, what are the factors that determine whether a gene is activated or switched off? How can we interfere with that? Another very hot area for us is the world of pattern recognition receptors. A very specific program, a key programme in our immune-inflammation therapy area unit, is around receptor-interacting protein 1 (RIP1) kinase, which plays a pivotal role in necrosis, apoptosis and necroptosis, all different forms of cell death, but also in cytokine signalling. So it plays a very important role in different diseases. Because this is such new biology, where we have developed a kinase inhibitor that only touches RIP1 kinase, you can see we have something that could be very interesting in terms of benefit-risk ratio. We have very strong preclinical package in a whole variety of disease models and we’ve published extensively on this. But then of course with such new biology the question is where is it going to
work? Therefore, we’re using a systematic experimental medicine approach, where in parallel we are testing the effects of a RIP1 kinase inhibitor in RA, psoriasis and ulcerative colitis, but there are also other programs outside the immune-inflammation area where we are exploring the role of RIP1 at this moment. So that is something that is very exciting for us. In addition, we have a focus on T-cell biology, especially Th17 biology, which is for us a very important field. We are also working on cytokines, chemokines and complement, and these are all key areas that I find very exciting at this moment in immuno-inflammation.

What have you discovered in your studies of vagus nerve stimulation in rheumatoid arthritis and why does the bioelectronic treatment approach hold promise for individuals with immune-mediated inflammatory disease?

This is work I completed outside of GSK. I am still affiliated at the University of Amsterdam and am still a non-salaried Professor there. I did this work during the last 10 years in Amsterdam and I’ve tried to complete that. I discovered that the so-called alpha-7 nicotinic acetylcholine receptor (alpha-7) plays a key role in the joints in controlling inflammation. This is how we got interested in it. I used alpha knockout mice and found that in models of chronic inflammation in RA these mice have increased arthritis and increased distortion of the joints. If you do the reverse and you give these mice nicotine, which triggers the alpha-7 receptor or specific alpha-7 agonists that activate this pathway, you can inhibit arthritis. In a collaboration with a company called SetPoint Medical, based in the US, we stimulated the vagus nerve, which also leads to activation of the same pathway, for 60 seconds per day and we found that you can reduce inflammation and protect joint destruction. We then did a clinical trial in humans and when we implanted the device in humans with RA, we could show there was a beneficial effect even in patents who are therapy resistant.

What research is GSK carrying out to help develop better treatments for RA?

We have several programs in RA, which is the most common chronic autoimmune disease. However, we are definitely not limited to RA in immuno-inflammation.

We have a focus on rheumatology, so also the other rheumatological syndromes like osteoarthritis,
Sjögren’s syndrome, systemic sclerosis etc., but also gastroenterology and dermatology, so that all sits in
immuno-inflammation. The programs that we have that are developing treatments for RA at this moment at GSK include the interleukin (IL)6 monoclonal antibody sirukumab, which is currently under review by the regulators. The difference between sirukumab and let’s say tocilizumab, the anti-IL6 receptor antibody from Roche which is on the market, or sarilumab, which was recently approved, is that these other two medicines target a receptor, whereas sirukumab targets the ligand. We partnered with Johnson & Johnson on that program. In addition, an anti-granulocyte macrophage colony-stimulating factor (GMCSF) monoclonal antibody is being tested for treatment of RA and currently in phase IIb trials. This may have different advantages compared to other medicines.

First it’s a very different pathway targeting really the key effector cells in RA, namely the macrophages in the synovial tissue and the neutrophils in the synovial fluid. It works in a slightly different way to TNF blockers and it actually targets the monocytes and the macrophages that are the major sources of proinflammatory cytokines in the joint. But it has also been shown in preclinical models that GM-CSFs play a particularly important role in pain, so we are quite interested in the specific effect on pain in RA and osteoarthritis. And then I think there is still an outstanding requirement for a safe and effective
small molecule and we hope that RIP1 kinase inhibitor might play that role. Then we have a few other programs that we have not disclosed as well.

What promising developments in the inflammation arena in general have made over the last couple of years, both by GSK and others?

Well I would pick probably the IL17 inhibitors and the IL23 inhibitors, as I think they are very important.
I think anti-GM-CSF also has enormous potential. We are very excited by this medicine for a variety of
immune mediated inflammatory disorders, some of which I have spoken about. I think we have a systematic approach to extend this to different indications, where a specific mechanism may play an important role. Again with RIP1 there is huge interest from the August 2017 © Biochemical Society 41
Interview scientific community, so I think that’s another very important development as well. And then of course there are the Janus kinase (JAK) inhibitors, the highly selective JAK1 inhibitors, which are of interest. Of course we need to see over time what the benefit-risk ratio is, if we get more experience, but definitely an interesting development.

In addition to developing new treatments for inflammatory disease, have you had much success repurposing old drugs for new indications?

I would not even call it repurposing of medicines, because ideally we need to do this at an early stage of
development and go into different indications where we believe a specific mechanism plays a role. I think RIP1 is probably a very good example, but for all medicines developed, we take the approach to investigate multiple indications. Especially in medical specialities like rheumatology and gastroenterology, what we call a disease is not really a disease, it’s a syndrome defined by clinical signs and symptoms. These conditions are heterogeneous, and may be driven by completely different mechanisms.

Interestingly, you can see on average the same efficacy if you treat a patient with RA with different
therapies that target different pathways. For example, TNF blockers compared to rituximab, which targets the B cells, compared to tocilizumab, which targets the IL6 receptor. The mechanisms are completely different, but also the patients who respond to these treatments not the same necessarily, highlighting the importance of individualized health care approaches to improve treatment effects. The other way around, all of these medicines may work in diseases other than RA. Another example would be belimumab, which has been approved for treatment of lupus now in four phase III clinical
trials. They were all positive which is quite amazing, because it’s such a difficult disease to treat and many
competing molecules have failed. Then the question is could it work in other autoantibody dependent immune mediated inflammatory disorders? And we’ve tested it in different conditions. There is a clinical trial going on in Sjögren’s syndrome, another autoimmune disease characterised by autoantibodies. We have also tested it in very rare diseases like idiopathic membranous glomerular nephritis, which is a truly autoantibody dependent disease. In a small experimental medicine study, we could show that there was a very significant decrease in the levels of autoantibodies, followed by a very significant decrease in proteinuria, which is a key hallmark of the disease. So that’s an example of what I call expansion of indications, where you really get more confidence in the mechanism and where you can see based on the molecular events rather than just on signs and symptoms. Maybe a good example from respiratory would be mepolizumab, an anti-interleukin 5 antibody that we have developed for asthma that we
are now testing in a variety of different diseases that are all characterised by increased eosinophils, because IL5 drives eosinophilia.

We have just announced that we are going to start a phase III clinical trial in nasal polyps. We are testing it in COPD, there is a condition called hypereosinophilic syndrome (HES) where we are testing it. There is a condition called eosinophilic granulomatosis with polyangiitis (EGPA). where we have published positive results. We are also testing it in atopic dermatitis, so I think that creates a very mature example of how based on the mechanism in common diseases like eczema, it is also possible to treat rare diseases like EGPA.

What do you think the future holds for inflammation research and the development of new therapies for inflammatory disease?

The future is to induce remission in all patients. Something that we only achieve in a minority of patients at the moment and in many diseases we don’t achieve it at all. To do this, we need to use different modalities where necessary. I spoke about small molecules and biopharmaceuticals, but we will also use other approaches. Ultimately the goal should be to cure the patients or to even prevent the disease. You may have heard me speak about type 1 diabetes in the past, which is also an autoimmune disease. Based on autoantibody profiles you can identify people who are at risk of developing the disease and during that stage you could perhaps interfere and stop the process from developing towards full-blown clinically established disease. I have done a similar study in RA, wearing my academic hat again. So I think that is the future – remission, cure, prevention – using different modalities and with a deep molecular understanding of the subsets of the disease.

Further Reading

  • Nature Jobs Blog: From academia to industry with Paul-Peter Tak –
  • GSK Website: Targeting the immune system through open innovation –
  • F. A. Koopman, M. A. van Maanen, M. J Vervoordeldonk, P. P. Tak. Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis. J Intern Med. 2017; 282(1):64-75.

Innovation in Development

Just over 140 years ago, the world’s first industrial-sized R&D laboratory opened. As someone who’s devoted his working life to finding new R&D breakthroughs, I’m envious of the explosion of activity that made the lab’s owner, Thomas Edison, one of history’s most remarkable inventors. But it’s his process of innovation that inspires me, as much as his life-changing creations.

  • 1
  • 2
Paul Peter Tak

© Paul Peter Tak.
All rights reserved.